Industry news

Q2 venture investing slows a tad, but the big money still flows into biotech

John Carroll / ENDPOINTS

Venture investing in biotech during the second quarter slowed somewhat from the blistering pace set in 2015, but the field still racked up another $1.7 billion, easily surpassing the mark for previous years and leaving 2016 on track to richly support the big new wave of drug developers in or near the clinic.

Russian pharma companies eye international expansion

Victoria Zavyalova / Russia Beyond the Headlines

Russian pharmaceutical companies are trying to attract foreign consumers with their high quality and reasonably-priced medicines. But first they need to strengthen their positions on the domestic market, which is still dominated by foreign companies.

Biotech VC: On track for second-highest year in 2016

Stacy Lawrence / Fierce Biotech

The stock market pullback and lackluster IPO market have weighed on biotech venture financing--but only a bit. The sector is still on track for its second-highest venture financing total ever, behind last year’s sums. That’s according to the latest data through the first half of this year from PricewaterhouseCoopers and the National Venture Capital Association.

Health spending in U.S. to rise 5.8 percent a year through 2025: CMS

Ransdell Pierson / Reuters

Healthcare spending in the United States will likely grow by an average 5.8 percent per year over the next decade, a bit faster than the past two years, due to an aging population, rising medical prices and faster economic growth, according to updated projections from the federal government released on Wednesday.

Partnership and licensing deal flows on pace for record year

Peter Winter / BioWorld

The insatiable appetite of companies for immuno-oncology assets is one of the main reasons that partnership and licensing deal flows remain on their torrid pace to eclipse the number and volume totals racked up last year.

15 July 2016

Pfizer links with NovaMedica to produce and market drugs in Russia

The Pharma Letter

US pharma giant Pfizer (NYSE: PFE) and NovaMedica, a company established by Russian high-technology investment fund Rusnano and American venture health care fund Domain Associates in 2012, have entered into an agreement to cooperate, signalling the development of a new partnership, to bring important medicines to the Russian market.

Can population management improve healthcare apps?

Beth Snyder Bulik / FiercePharmaMarketing

In an increasingly mobile-first world, apps help people manage their lives and health. But could healthcare apps work better if they were supported by population management systems?

Are Facebook’s new disappearing messages a new opportunity for pharma? Not yet, expert says

Beth Snyder Bulik / FiercePharmaMarketing

Taking a page from Snapchat, Facebook ($FB) this week began testing disappearing messages for its Messenger service. But pharma marketers may want to hold off on embracing the new tool.

The 15 top R&D spenders in the global biopharma business

John Carroll / ENDPOINTS

Over the past nine years that I’ve been analyzing Big Pharma’s R&D numbers, there’s been some fluctuation in the top ten, but overall spending has remained fairly steady at roughly $70 billion a year

EMA Releases Statement on Brexit

BioPharm International

The European Medicines Agency (EMA) says the future location of the agency will be determined by common agreement between representatives of the Member States, according to a July 6, 2016 statement. Until then, EMA says it will be conducting business as usual, and the outcome of the June 23 referendum will not affect the agency’s operations.